Vivos Therapeutics (NASDAQ: VVOS) reported Q1 EPS of ($0.45), $0.04 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.02 million versus the consensus estimate of $4.1 million.

For earnings history and earnings-related data on Vivos Therapeutics (VVOS) click here.